Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

This study tests whether adding an immunotherapy drug called benmelstobart to chemotherapy and radiation therapy before surgery can improve outcomes in people with resectable (surgically removable) esophageal squamous cell cancer (a cancer of the food pipe). **You may be eligible if...** - You are 18 or older with histologically confirmed esophageal squamous cell cancer - Your cancer is at a resectable stage (T1-3N+M0 or T3NanyM0) - You have not received any prior cancer treatment for your esophageal cancer - Your blood counts, liver, kidney, and heart function meet required levels - You are willing to use contraception during and for 6 months after the study **You may NOT be eligible if...** - You have other active cancers - You have had prior radiation to the chest or esophagus - You have active autoimmune disease or are on immunosuppressive medications - You are pregnant or breastfeeding - You have uncontrolled infections or serious heart problems Talk to your doctor to see if this trial is right for you.